utomilumab: Clinical Trials

2 trials of utomilumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 terminated. 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 32Active not recruiting 1, Terminated 1

Follow utomilumab: new trials by email Literature Review of utomilumab trials Research Report on utomilumab

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Avelumab, Lorlatanib, Talazoparib - Advanced Malignancies, NSCLC
Phase 3Active not recruitingPfizer772021-09-292026-10-20
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Avelumab, Utomilumab, Rituximab - Diffuse Large B-Cell Lymphoma
Phase 3TerminatedPfizer292016-12-162020-12-17

Conditions studied

Lymphoma, Large B-Cell, Diffuse (1)  ·  Ovarian Neoplasms (1)

Sponsors

Pfizer (2)

Countries

Australia (2)  ·  Belgium (2)  ·  Italy (2)  ·  Poland (2)  ·  South Korea (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  United States (2)  ·  Canada (1)  ·  Denmark (1)  ·  France (1)  ·  Hungary (1)  ·  Israel (1)  ·  Japan (1)  ·  Mexico (1)

Results publications

PMID 34687398

NIH funding

2016 (1), 2023 (1)